Teva Pharmaceutical Industries Ltd (TEVA) stock
TEVANYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/30128% above fair value
$42.62+0.05 (+0.12%)
Close on Nov 17, 2026Market cap $49.66BP/E 71.0Yield –
Teva Pharmaceutical Industries free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Teva Pharmaceutical Industries's free cash flow for the twelve months ending Jun 30, 2026 was $1.35B, up 51.5% year over year. For fiscal 2025 it was $1.15B, up 53.3% from the year before. Over ten years it grew -13.3% a year on average. The highest annual figure on record is $4.77B in fiscal 2015.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.15B | +53.3% |
| FY2024 | Dec 31, 2024 | $749.00M | -11.0% |
| FY2023 | Dec 31, 2023 | $842.00M | -19.2% |
| FY2022 | Dec 31, 2022 | $1.04B | +341.5% |
| FY2021 | Dec 31, 2021 | $236.00M | -63.0% |
| FY2020 | Dec 31, 2020 | $638.00M | +186.1% |
| FY2019 | Dec 31, 2019 | $223.00M | -87.6% |
| FY2018 | Dec 31, 2018 | $1.80B | +32.9% |
| FY2017 | Dec 31, 2017 | $1.35B | -54.8% |
| FY2016 | Dec 31, 2016 | $2.99B | -37.3% |
| FY2015 | Dec 31, 2015 | $4.77B | +13.6% |
| FY2014 | Dec 31, 2014 | $4.20B | +90.3% |
| FY2013 | Dec 31, 2013 | $2.21B | -36.4% |
| FY2012 | Dec 31, 2012 | $3.47B | +12.6% |
| FY2011 | Dec 31, 2011 | $3.08B | -10.1% |
| FY2010 | Dec 31, 2010 | $3.43B | +29.1% |
| FY2009 | Dec 31, 2009 | $2.65B | +4.1% |
| FY2008 | Dec 31, 2008 | $2.55B | +100.6% |
| FY2007 | Dec 31, 2007 | $1.27B | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $307.00M | +134.4% |
| Q1 FY2026 | Mar 31, 2026 | -$208.00M | – |
| Q4 FY2025 | Dec 31, 2025 | $1.02B | +127.8% |
| Q3 FY2025 | Sep 30, 2025 | $233.00M | -57.2% |
| Q2 FY2025 | Jun 30, 2025 | $131.00M | +2083.3% |
| Q1 FY2025 | Mar 31, 2025 | -$232.00M | – |
| Q4 FY2024 | Dec 31, 2024 | $446.00M | -58.1% |
| Q3 FY2024 | Sep 30, 2024 | $545.00M | – |
| Q2 FY2024 | Jun 30, 2024 | $6.00M | -97.1% |
| Q1 FY2024 | Mar 31, 2024 | -$248.00M | – |
| Q4 FY2023 | Dec 31, 2023 | $1.07B | +28.2% |
| Q3 FY2023 | Sep 30, 2023 | -$144.00M | -134.2% |
| Q2 FY2023 | Jun 30, 2023 | $205.00M | – |
| Q1 FY2023 | Mar 31, 2023 | -$284.00M | – |
| Q4 FY2022 | Dec 31, 2022 | $831.00M | +174.3% |
| Q3 FY2022 | Sep 30, 2022 | $421.00M | +9.9% |
| Q2 FY2022 | Jun 30, 2022 | -$4.00M | -103.8% |
| Q1 FY2022 | Mar 31, 2022 | -$206.00M | – |
| Q4 FY2021 | Dec 31, 2021 | $303.00M | +95.5% |
| Q3 FY2021 | Sep 30, 2021 | $383.00M | +133.5% |
| Q2 FY2021 | Jun 30, 2021 | $105.00M | -26.1% |
| Q1 FY2021 | Mar 31, 2021 | -$555.00M | -413.6% |
| Q4 FY2020 | Dec 31, 2020 | $155.00M | -63.0% |
| Q3 FY2020 | Sep 30, 2020 | $164.00M | +5.1% |
| Q2 FY2020 | Jun 30, 2020 | $142.00M | – |
| Q1 FY2020 | Mar 31, 2020 | $177.00M | – |
| Q4 FY2019 | Dec 31, 2019 | $419.00M | +172.1% |
| Q3 FY2019 | Sep 30, 2019 | $156.00M | -44.7% |
| Q2 FY2019 | Jun 30, 2019 | -$339.00M | -1403.8% |
| Q1 FY2019 | Mar 31, 2019 | -$13.00M | -101.0% |
| Q4 FY2018 | Dec 31, 2018 | $154.00M | -74.0% |
| Q3 FY2018 | Sep 30, 2018 | $282.00M | -51.6% |
| Q2 FY2018 | Jun 30, 2018 | $26.00M | -89.3% |
| Q1 FY2018 | Mar 31, 2018 | $1.33B | – |
| Q4 FY2017 | Dec 31, 2017 | $592.00M | – |
| Q3 FY2017 | Sep 30, 2017 | $583.00M | -53.0% |
| Q2 FY2017 | Jun 30, 2017 | $242.00M | – |
| Q1 FY2017 | Mar 31, 2017 | -$66.00M | – |
| Q4 FY2016 | Dec 31, 2016 | -$243.00M | – |
| Q3 FY2016 | Sep 30, 2016 | $1.24B | – |
See a number that looks wrong?